Home » Venture Capital » Current Portfolio

Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Companysort icon Description Status Initial Date
<a href="/venture-capital/all-companies/novomer-inc">Novomer, Inc.</a> Pioneering a family of high performance, environmentally responsible polymers and chemical intermediates. Private 2007 View Profile
<a href="/venture-capital/all-companies/oasys-water-inc">Oasys Water, Inc.</a> Develops systems to maximize fresh water availability while reducing the energy and cost associated with desalination. Private 2009 View Profile
<a href="/venture-capital/all-companies/permeon-biologics-inc">Permeon Biologics Inc.</a> Pioneering a breakthrough class of intracellular biologics that target a broad spectrum of previously undruggable targets. Private 2011 View Profile
<a href="/venture-capital/all-companies/pronutria">Pronutria</a> Transforming global nutrition. Private 2010 View Profile
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing a novel platform for single molecule analysis of proteins. Private 2007 View Profile
<a href="/venture-capital/all-companies/receptos-inc">Receptos, Inc.</a> Developing therapeutic candidates for the treatment of immune and metabolic diseases. Public 2009 View Profile
<a href="/venture-capital/all-companies/seahorse-bioscience-inc">Seahorse Bioscience, Inc.</a> Analytical instruments and consumable labware products for biological research and drug discovery. Private 2001 View Profile
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Private 2008 View Profile
<a href="/venture-capital/all-companies/selventa">Selventa</a> Analyzes molecular patient data, accelerates the development process and clarifies decisions on therapeutics and diagnostics Private 2001 View Profile
<a href="/venture-capital/all-companies/seres-health">Seres Health</a> Seres Health is pioneering a new class of therapeutics that, for the first time, catalyzes health in multiple important therapeutic areas. Private 2012 View Profile
<a href="/venture-capital/all-companies/seventh-sense-biosystems-inc">Seventh Sense Biosystems, Inc.</a> Optimizing the interface of diagnostic medicine and the healthcare consumer by simplifying blood sampling and testing. Private 2007 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Developing next-generation medical diagnostic products. Private 2006 View Profile
<a href="/venture-capital/all-companies/tangent-medical-technologies-inc">Tangent Medical Technologies Inc.</a> Tangent Medical Technologies is advancing infusion therapy by improving catheter stability, patient comfort and healthcare worker safety with its proprietary, intravenous catheters and associated products. Private 2011 View Profile
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing local minimally-invasive drug-device convergence products. Private 2008 View Profile
<a href="/venture-capital/all-companies/tetraphase-pharmaceuticals-inc">Tetraphase Pharmaceuticals, Inc.</a> Creating novel antibiotics for serious and life-threatening multi-drug resistant infections. Public 2006 View Profile
<a href="/venture-capital/all-companies/transmedics-inc">TransMedics, Inc.</a> Developed the first commercial, portable warm blood perfusion system that allows for a new type of organ transplant. Private 2010 View Profile
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/wikicell-designs">WikiCell Designs</a> WikiCell Designs is developing deliciously edible forms of packaging that enclose food or drinks in ways similar to how nature protects foods. Private 2012 View Profile